n by solid sales growth in Novo Nordisk® Growth drivers for the first half of 2020 International Operations sales growth of 12% at CER • Sales growth driven by all areas • Growth was impacted by COVID-19-related stocking and other timing events, partially offset by fewer patients initiating treatment North America Operations sales increased by 1% at CER • Sales growth positively impacted by first quarter 2020 surge in demand • Surge in demand largely offset by fewer patients initiating treatment and less use of NovoSeven® due to the lockdown ld; NAO: North America Operations
Download PDF file